Cyclacel Pharmaceuticals, Inc.

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

SELLAS Life Sciences Group, Inc. is in a strong position in acute myeloid leukemia (AML) with positive data from a Phase IIa study of SLS009 and the completion of enrollment in its Phase III trial of

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

CDK4/6 inhibitors – Eli Lilly and Company ’s Verzenio, Novartis AG ’s Kisqali and Pfizer Inc. ’s Ibrance – have proven efficacy in ER-positive/Her2-negative breast cancer, but a significant proport